Evidence map›Paper›PMID 32843618›Full record

ArticleNature communications2020

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.

Ying Ji, Xiangsheng Liu, Juan Li, Xiaodong Xie, Max Huang, Jinhong Jiang, Yu-Pei Liao, Timothy Donahue, Huan Meng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Targeting CDK4 and CDK6 in cancer.Nature reviews. Cancer · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Ying Ji *Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Xiangsheng Liu *Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-5719-2838
Juan LiDivision of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0003-4110-3295
Xiaodong XieDivision of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Max HuangDivision of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0003-4580-1656
Jinhong JiangCalifornia NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Yu-Pei LiaoDivision of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Timothy DonahueDepartment of Surgery, University of California, Los Angeles, CA, 90095, USA.
Huan MengDivision of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA. menghuan@g.ucla.edu.ORCID http://orcid.org/0000-0001-8844-3938
California NanoSystems Institute · USUniversity of California, Los Angeles · US

Funding

UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

Aberrant cell cycle machinery and loss of the CDKN2A tumor suppressor locus make CDK4/6 a potential target in pancreatic ductal adenocarcinoma (PDAC). However, a vast majority of PDAC cases do not harbor a durable response to monotherapy of CDK4/6 inhibitor. Utilizing remote loading to co-encapsulate CDK4/6 inhibitor palbociclib (PAL) and an autophagy inhibitor hydroxychloroquine (HCQ), we demonstrate a ratiometrically designed mesoporous silica nanoformulation with synergistic efficacy in subcutaneous and orthotopic PDAC mouse models. The synergism is attributed to the effective intratumoral buildup of PAL/HCQ, which otherwise exhibit distinctly different circulatory and biodistribution profile. PAL/HCQ co-delivery nanoparticles lead to the most effective shrinkage of PDAC compared to various controls, including free drug mixture. Immunohistochemistry reveals that PAL/HCQ co-delivery nanoparticles trigger anti-apoptotic pathway after repetitive intravenous administrations in mice. When combined with a Bcl inhibitor, the performance of co-delivery nanoparticles is further improved, leading to a long-lasting anti-PDAC effect in vivo.

Indexed as

Drug Delivery SystemsAnimalsApoptosisAutophagyCarcinoma, Pancreatic DuctalCell Line, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Disease Models, AnimalDrug SynergismHumansHydroxychloroquineMiceNanoparticlesPancreatic NeoplasmsPiperazinesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HydroxychloroquinepalbociclibPiperazinesPyridinesSilicon Dioxide

Identifiers

PMID32843618
PMCPMC7447818
OpenAlexW3080369605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.